187 related articles for article (PubMed ID: 30589832)
21. Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program.
Kutsenko A; Berrington de Gonzalez A; Curtis RE; Rajaraman P
Cancer Causes Control; 2014 Jun; 25(6):659-68. PubMed ID: 24682745
[TBL] [Abstract][Full Text] [Related]
22. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer.
Galper S; Gelman R; Recht A; Silver B; Kohli A; Wong JS; Van Buren T; Baldini EH; Harris JR
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):406-14. PubMed ID: 11872286
[TBL] [Abstract][Full Text] [Related]
23. Increased risk of second malignant neoplasms in adolescents and young adults with cancer.
Lee JS; DuBois SG; Coccia PF; Bleyer A; Olin RL; Goldsby RE
Cancer; 2016 Jan; 122(1):116-23. PubMed ID: 26441212
[TBL] [Abstract][Full Text] [Related]
24. Second cancers in patients with neuroendocrine tumors.
Tsai HJ; Wu CC; Tsai CR; Lin SF; Chen LT; Chang JS
PLoS One; 2013; 8(12):e86414. PubMed ID: 24392036
[TBL] [Abstract][Full Text] [Related]
25. Increased risk of second malignant neoplasms outside radiation fields in patients with cervical carcinoma.
Werner-Wasik M; Schmid CH; Bornstein LE; Madoc-Jones H
Cancer; 1995 May; 75(9):2281-5. PubMed ID: 7712437
[TBL] [Abstract][Full Text] [Related]
26. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
Ai WZ; Keegan TH; Press DJ; Yang J; Pincus LB; Kim YH; Chang ET
JAMA Dermatol; 2014 Jul; 150(7):709-15. PubMed ID: 24718769
[TBL] [Abstract][Full Text] [Related]
27. Second primary lung cancer in United States Cancer Survivors, 1992-2008.
Donin NM; Kwan L; Lenis AT; Drakaki A; Chamie K
Cancer Causes Control; 2019 May; 30(5):465-475. PubMed ID: 30900065
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data.
Gordon-Dseagu VL; Devesa SS; Goggins M; Stolzenberg-Solomon R
Int J Epidemiol; 2018 Apr; 47(2):427-439. PubMed ID: 29149259
[TBL] [Abstract][Full Text] [Related]
29. The risk of subsequent primary carcinoma of the pancreas in patients with cutaneous malignant melanoma.
Schenk M; Severson RK; Pawlish KS
Cancer; 1998 May; 82(9):1672-6. PubMed ID: 9576287
[TBL] [Abstract][Full Text] [Related]
30. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries.
Zhu G; Chen Y; Zhu Z; Lu L; Bi X; Deng Q; Chen X; Su H; Liu Y; Guo H; Zheng T; Yu H; Zhang Y
Dis Esophagus; 2012 Aug; 25(6):505-11. PubMed ID: 22067063
[TBL] [Abstract][Full Text] [Related]
31. A population-based analysis of a rare oncologic entity: Malignant pancreatic tumors in children.
Mylonas KS; Nasioudis D; Tsilimigras DI; Doulamis IP; Masiakos PT; Kelleher CM
J Pediatr Surg; 2018 Apr; 53(4):647-652. PubMed ID: 28693851
[TBL] [Abstract][Full Text] [Related]
32. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.
Kleinerman RA; Tucker MA; Abramson DH; Seddon JM; Tarone RE; Fraumeni JF
J Natl Cancer Inst; 2007 Jan; 99(1):24-31. PubMed ID: 17202110
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours.
Clift AK; Drymousis P; Al-Nahhas A; Wasan H; Martin J; Holm S; Frilling A
Neuroendocrinology; 2015; 102(1-2):26-32. PubMed ID: 25824138
[TBL] [Abstract][Full Text] [Related]
34. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975-2001.
Ahmed F; Goodman MT; Kosary C; Ruiz B; Wu XC; Chen VW; Correa CN
Cancer; 2006 Sep; 107(5 Suppl):1162-71. PubMed ID: 16838312
[TBL] [Abstract][Full Text] [Related]
35. Second malignant neoplasms among children, adolescents and young adults with Wilms tumor.
Lee JS; Padilla B; DuBois SG; Oates A; Boscardin J; Goldsby RE
Pediatr Blood Cancer; 2015 Jul; 62(7):1259-64. PubMed ID: 25809878
[TBL] [Abstract][Full Text] [Related]
36. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
Hisada M; Chen BE; Jaffe ES; Travis LB
J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
[TBL] [Abstract][Full Text] [Related]
37. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.
Scherübl H; Streller B; Stabenow R; Herbst H; Höpfner M; Schwertner C; Steinberg J; Eick J; Ring W; Tiwari K; Zappe SM
World J Gastroenterol; 2013 Dec; 19(47):9012-9. PubMed ID: 24379626
[TBL] [Abstract][Full Text] [Related]
38. Risk of Second Primary Cancer in Survivors of In Situ Melanoma.
Kimlin MG; Youlden DR; Brodie AM; DiSipio T; Youl P; Nair-Shalliker V; Baade PD
J Invest Dermatol; 2019 Apr; 139(4):842-847. PubMed ID: 30423330
[TBL] [Abstract][Full Text] [Related]
39. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries.
Olsen JH; Möller T; Anderson H; Langmark F; Sankila R; Tryggvadóttír L; Winther JF; Rechnitzer C; Jonmundsson G; Christensen J; Garwicz S
J Natl Cancer Inst; 2009 Jun; 101(11):806-13. PubMed ID: 19470947
[TBL] [Abstract][Full Text] [Related]
40. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors.
Qadan M; Ma Y; Visser BC; Kunz PL; Fisher GA; Norton JA; Poultsides GA
J Am Coll Surg; 2014 Feb; 218(2):188-95. PubMed ID: 24321190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
